Table 2 Outcomes by treatment and primary tumour location in PRIME and PEAK

From: Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials

Characteristic

PRIME

PEAK

Panitumumab + FOLFOX4

FOLFOX4

Panitumumab + mFOLFOX6

Bevacizumab + mFOLFOX6

Left (n = 169)

Right (n = 39)

Left (n = 159)

Right (n = 49)

Left (n = 53)

Right (n = 22)

Left (n = 54)

Right (n = 14)

Median PFS (95% CI), months

12.9

(10.0–14.6)

7.5

(5.5–10.4)

9.2

(7.6–10.7)

7.0

(5.4–8.0)

14.6

(11.6–17.7)

8.7

(5.7–10.9)

11.5

(9.3–13.0)

12.6

(1.8–16.6)

Median OS (95% CI), months

30.3

(25.8–36.1)

11.1

(8.1–25.2)

23.6

(18.2–26.9)

15.4

(9.1–21.7)

43.3

(31.6–63.0)

17.5

(9.1–30.7)

32.0

(26.0–47.4)

21.0

(6.0–29.0)

Objective response ratea, n/N (%)

114/168 (68)

16/38 (42)

82/156 (53)

16/46 (35)

34/53 (64)

14/22 (64)

31/54 (57)

7/14 (50)

ETSb ≥30%, n (%)

104 (62)

12 (31)

57 (36)

15 (31)

31 (58)

12 (55)

22 (41)

3 (21)

 Median PFS (95% CI), months

14.8

(12.5–18.5)

14.9

(7.4–27.2)

11.1

(9.3–13.9)

7.3

(5.6–11.1)

16.2

(13.0–20.3)

10.8

(5.5–15.8)

12.9

(9.3–18.6)

18.4

(16.6–21.4)

 Median OS (95% CI), months

35.0

(29.8–41.9)

27.2

(8.0–57.4)

31.7

(23.8–38.1)

23.6

(7.2–34.5)

55.4

(41.3–63.0)

24.6

(10.3–48.4)

48.5

(28.9–NE)

26.2

(21.0–31.3)

ETSb <30%, n (%)

49 (29)

22 (56)

87 (55)

27 (55)

20 (38)

7 (32)

28 (52)

9 (64)

 Median PFS (95% CI), months

9.4

(5.8–13.8)

6.5

(4.0–9.9)

6.9

(5.5–7.8)

6.9

(3.6–11.9)

11.6

(7.5–16.4)

5.8

(3.6–9.8)

12.4

(7.4–13.0)

12.6

(1.8–13.8)

 Median OS (95% CI), months

19.9

(13.5–27.5)

10.6

(6.1–22.5)

17.2

(14.2–20.7)

13.1

(6.1–18.8)

34.2

(17.3–48.0)

15.3

(5.8–46.1)

27.7

(21.0–32.0)

23.3

(6.0–29.0)

Median DpR (IQR), %

59* (37–73)

37* (12–52)

49 (27–67)

50 (21–65)

70* (47–100)

50* (23–70)

48 (29–80)

45 (16–56)

Any resection, n (%)

25 (15)

4 (10)

21 (13)

6 (12)

9 (17)

2 (9)

10 (19)

1 (7)

R0 resection, n (%)

19 (11)

2 (5)

16 (10)

1 (2)

7 (13)

1 (5)

6 (11)

1 (7)

Any resection—LLD population, n/N (%)

10/33 (30)

2/6 (33)

8/31 (26)

2/5 (40)

5/18 (28)

1/4 (25)

6/15 (40)

1/4 (25)

R0 resection—LLD population, n/N (%)

9/33 (27)

2/6 (33)

6/31 (19)

0/5 (0)

4/18 (22)

1/4 (25)

5/15 (33)

1/4 (25)

  1. CI confidence interval, DpR depth of response, ETS early-tumour shrinkage, IQR interquartile range, LLD liver-limited disease, mFOLFOX6 modified FOLFOX6, NE not evaluable, OS overall survival, PFS progression-free survival, R0 complete resection.
  2. *p-value for difference between tumour side <0.05.
  3. aDenominator is the number of patients evaluable for response.
  4. bETS status was unknown for some patients
Back to article page